Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Everett E Vokes
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma–associated sinonasal squamous cell carcinoma
Abstract Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy arising de novo or from inverted papilloma (IP), a benign neoplasm with malignant potential. The molecular drivers of IP-associated SNSCC (IP-SNSCC) remain poorly defined, and no effective therapies are available. Progress is hindered by limited preclinical studies and prospective clinical investigations.
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer : A Randomized Clinical Trial
|
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer: A Randomized Clinical Trial Supplement 1. Supplement 2. eFigure 1. Disease-free survival sensitivity analysis excluding new primary lung cancers eFigure 2. Disease-free survival in patients with negative and low tumoral PD-L1 eTable 1. Grade 3-5 Treatment-related Toxicities per CTCAE v4.0 eTable 2. Treatment-related Grade 3-5 Events Occurring in ≥ 1% of patients (n,%) Supplement 3.
By Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin, Charles Simone, Kurt R. Oettel, David Kozono, Rajitha Sunkara, Bryan Faller, James M. Isbell, Vladimir Hugec, Jeffrey M. Clarke, Ramaswamy Govindan, Jacob Sands, John Heymach, Luis E Raez, Shakun Malik, Thomas E. Stinchcombe, Sumithra J. Mandrekar, Jeffrey Bradley, David E. Gerber, Everett E Vokes, David Gandara, Charles Staley, Suresh S. Ramalingam, Onkar V. Khullar, Asheesh Shipstone, Eric C. McGary, Ashita Talsania
|
JAMA: Journal of the American Medical Association
Verified
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial
Abstract Preclinical studies have evaluated murine double minue 2 (MDM2) inhibitors as a treatment for adenoid cystic carcinoma (ACC), but clinical trials are lacking. This phase I trial (NCT03781986) assesses the safety and antitumor activity of an oral MDM2 inhibitor, alrizomadlin (APG-115), +/- carboplatin in TP53 wild type unresectable recurrent/metastatic salivary gland cancers (R/M SGC) with a planned 1:1 randomization to carboplatin chemotherapy.
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer | NEJM
Published June 18, 2025 DOI: 10.1056/NEJMe2506751 For permission requests, please contact NEJM Reprints at reprints@nejm.org Notes This editorial was published on June 18, 2025, at NEJM.org. Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.
2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation
AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
Hispanic children with high-risk neuroblastoma have worse survival outcomes
Source/Disclosures Source: Umaretiya PJ, et al. Abstract 10005. Scheduled for presentation at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Disclosures: Umaretiya reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Inequities observed in telemedicine use for cancer care during COVID-19 pandemic
Source/Disclosures Source: Guadamuz JS, et al. Abstract 6511. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Disclosures: Flatiron Health supported the study. Guadamuz reports employment with and stock ownership in Flatiron Health. Please see the abstract for all researchers’ relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Innovation Can Advance Equitable Cancer Care
By Everett Vokes, MD, FASCO May 25, 2022 The North Star of an organization is its mission statement. At ASCO, no initiative gets the green light unless it can fulfill the Society’s mission.
A Global Approach to Cancer Equity in the Hispanic/Latinx Population
DOI: 10.1200/OP.22.00225 JCO Oncology Practice - published online before print May 11, 2022
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology
Historically, 5-year survival rates of patients with advanced non–small-cell lung cancer (NSCLC) who received chemotherapy were < 5%.1 Effective treatment options for patients without targetable molecular alterations, particularly for those who progressed after first-line chemotherapy, were limited until recently.
Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy
Authors: Shawn Kothari, Everett E. Vokes Abstract Immunotherapy has emerged as a new standard of care therapeutic option for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma. Following the recent presentation of Keynote-048, the use of Pembrolizumab either as a single agent or in combination with chemotherapy can be considered as first-line treatment for patients with measurable PD-L1 in their tumor or microenvironment (1).
Prolonging Life, but at What Price?
[Skip to Content Landing] Sign in to your personal account Institutional sign in: OpenAthens | Shibboleth Purchase access Buy this article and get unlimited access and a printable PDF ($30.00) - Sign in or create a free account Rent this article for read-only access ($8.99) Sign in to download free article PDFs Sign in to your personal account Institutional sign in: OpenAthens | Shibboleth Get free access to newly published articles Create a personal account or sign in to: Register for email...
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that belongs to the ErbB family. Alterations in EGFR have long been considered an oncogenic stimulus in head and neck squamous cell carcinoma (HNSCC). Observed EGFR modifications in HNSCC include overexpression, amplification, and activating mutations.
Palbociclib: a new partner for cetuximab?
1 Vermorken JB Trigo J Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25 : 2171-2177 Recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) remains a substantial health problem.
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study: Journal of Clinical Oncology: Vol 0, No 0
As symptomatic brain metastases are devastating for patients, impairing quality of life (QoL), 13 we have performed a randomized study to investigate whether PCI reduces the proportion of patients with symptomatic brain metastases.
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study: Journal of Clinical Oncology: Vol 0, No 0
Patients with stage III NSCLC—staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging—were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery.
ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards
Towards personalised medicine in lung and thymus neuroendocrine tumours
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Everett E
Contact Everett E, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack